T Christopher Uchida Sells 791 Shares of Palomar (NASDAQ:PLMR) Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) CFO T Christopher Uchida sold 791 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $127.74, for a total value of $101,042.34. Following the transaction, the chief financial officer directly owned 16,238 shares of the company’s stock, valued at approximately $2,074,242.12. This represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palomar Price Performance

Shares of NASDAQ PLMR opened at $130.09 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.50 and a current ratio of 0.50. Palomar Holdings, Inc. has a fifty-two week low of $100.81 and a fifty-two week high of $147.62. The firm has a market capitalization of $3.42 billion, a PE ratio of 17.49 and a beta of 0.40. The stock’s 50-day simple moving average is $130.76 and its 200-day simple moving average is $123.92.

Palomar (NASDAQ:PLMR) last posted its earnings results on Tuesday, August 4th. The company reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.17. The firm had revenue of $314.42 million during the quarter, compared to analysts’ expectations of $621.52 million. Palomar had a return on equity of 23.28% and a net margin of 18.61%.During the same quarter in the previous year, the business earned $1.76 earnings per share. As a group, equities research analysts forecast that Palomar Holdings, Inc. will post 9.21 EPS for the current fiscal year.

Palomar Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. Stockholders of record on Wednesday, August 19th will be issued a $0.45 dividend. The ex-dividend date is Wednesday, August 19th. This represents a $1.80 annualized dividend and a dividend yield of 1.4%. Palomar’s dividend payout ratio is presently 24.19%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. acquired a new stake in shares of Palomar during the fourth quarter worth about $32,000. Kestra Advisory Services LLC acquired a new position in Palomar in the 4th quarter valued at about $33,000. Rockefeller Capital Management L.P. raised its stake in Palomar by 81.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock valued at $40,000 after acquiring an additional 132 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Palomar during the 2nd quarter valued at approximately $43,000. Finally, Frazier Financial Advisors LLC acquired a new stake in Palomar during the 4th quarter worth approximately $54,000. 90.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PLMR. Evercore set a $152.00 price target on shares of Palomar in a research report on Friday, July 10th. Zacks Research cut Palomar from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. boosted their target price on Palomar from $150.00 to $167.00 and gave the company an “overweight” rating in a report on Monday, July 20th. Keefe, Bruyette & Woods upped their target price on Palomar from $166.00 to $167.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Finally, Weiss Ratings upgraded Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 18th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.75.

Palomar News Summary

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Strong premium growth and expansion in specialty insurance are expected to support Palomar’s earnings momentum. Analysts’ average price target of $162.75 and recent target increases reinforce the bullish view. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?
• Positive Sentiment: Dowling & Partners expressed a positive view of Palomar’s fiscal 2026 earnings outlook, adding to expectations for continued profit growth. DOWLING & PARTN Has Positive View of Palomar FY2026 Earnings
• Positive Sentiment: Palomar’s latest quarterly results provide fundamental support: earnings per share of $2.36 exceeded the $2.19 consensus estimate, while profitability and return on equity remained strong.
• Neutral Sentiment: Several insiders, including the president, CFO and Jonathan Knutzen, sold relatively small portions of their holdings to cover tax withholding on vested equity awards. Because the transactions were not discretionary sales, they are less negative than typical insider selling, though they may limit near-term sentiment.
• Neutral Sentiment: Palomar declared a quarterly dividend of $0.45, equivalent to $1.80 annually and a yield of approximately 1.4%, providing modest shareholder support.
• Negative Sentiment: Competitive pricing could reduce premium profitability, while a higher combined ratio would pressure underwriting margins. These risks may temper the market’s response to otherwise strong growth expectations. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?

Palomar Company Profile

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.